Relmada Therapeutics, Inc company logo — Pharmaceutical Manufacturing
Relmada Therapeutics, Inc Email Format

Relmada Therapeutics, Inc

Pharmaceutical Manufacturing
Coral Gables, Florida

About Relmada Therapeutics, Inc

Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations.

Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase 2b-ready investigational program for compulsion-related disorders including Tourette’s Syndrome and Prader-Willi syndrome, into further studies.

For more information, visit www.relmada.com.

Find Relmada Therapeutics, Inc Execs' Valid Emails

Up to 90% verified emails and mobile numbers, refreshed weekly.

Company Details

Annual Revenue
0-500K
Industry
Pharmaceutical Manufacturing
Size
11-50 employees
Type
Public Company
Location
Coral Gables, Florida
Country
United States

Frequently Asked Questions about

Relmada Therapeutics, Inc operates in the Pharmaceutical Manufacturing industry and is headquartered in United States.

Relmada Therapeutics, Inc has approximately 11-50 employees employees.

Relmada Therapeutics, Inc is based in Coral Gables, Florida, United States.

Yes. Relmada Therapeutics, Inc is a publicly traded company.

You can reach Relmada Therapeutics, Inc’s investor relations department through the contact section on their official website or directly via the investor relations email listed in their latest SEC filings.

Find verified emails and phone numbers for professionals like those at

Up to 90% verified emails and mobile numbers, backed by weekly job-change alerts.

Find verified emails at this company

An email pattern tells you the format. It does not tell you who works there now or whether an address still delivers. Scalelist returns verified contacts, checked at the point you build the list.